French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

The Lymphoma Academic Research Organisation36 个研究点分布在 1 个国家目标入组 5,000 人2019年12月19日

适应症Hematopathology Eligible or CAR-t Cell Treatment

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: Hematopathology Eligible or CAR-t Cell Treatment
发起方: The Lymphoma Academic Research Organisation
入组人数: 5000
试验地点: 36
主要终点: overall survival from eligibility
状态: 招募中
最后更新: 上个月

概览研究者入排标准结局指标研究点相似试验

概览

简要总结

This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.

注册库

clinicaltrials.gov

开始日期

2019年12月19日

结束日期

2038年12月19日

最后更新

上个月

研究类型

Observational

性别

All

研究者

发起方

The Lymphoma Academic Research Organisation

责任方

Sponsor

入排标准

入选标准

•Retrospective inclusion :
•Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
•If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
•Prospective inclusion :
•Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
•Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
•Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
•If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.